Nivolumab is one anti–programmed death 1 (PD-1) monoclonal antibody that has been shown to bring long-term overall survival (OS) benefits in the case of platinum-refractory HNSCC, compared to single agent chemotherapy treatment [1]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.